

Blinded Treatment Phase
Optional Extended Treatment Phase
Arm A
Chemotherapy
(Taxane [Docetaxel, Paclitaxel, or Paclitaxel Protein-bound], Gemcitabine, Vinorelbine, or Capecitabine) as Determined by the Investigator Prior to Randomization
+
Bevacizumab
(15 mg/kg IV q 3 Weeks or 10 mg/kg q 2 Weeks)
Subjects with Previously Treated Metastatic Breast Cancer
Arm B
Chemotherapy
(Taxane [Docetaxel, Paclitaxel, or Paclitaxel Protein-bound], Gemcitabine, Vinorelbine, or Capecitabine) as Determined by the Investigator Prior to Randomization
+
Placebo
(IV q 2 or 3 Weeks, Depending on Chemotherapy Regimen)
Open-Label Bevacizumab
Either 15 mg/kg IV Every 3 Weeks or 10 mg/kg IV Every 2 Weeks; Given Concurrently with Chemotherapy, as per Investigator Discretion

FIG. 1




Primary Endpoint of PFS, ITT Population
Median PFS, 7.2 vs. 5.1 Months
HR = 0.78, p = 0.0072
Chemo/BV (n=459)
Chemo/Placebo (n=225)
Proportion of Progression-free
Duration of Progression-free Survival (Months)
Number at Risk:
Chemo/Placebo 225 165 129 93 77 44 33 19 12 8 5 4 3 1 1 0 0 0
Chemo/BV 459 381 334 254 190 130 87 47 27 18 9 5 2 1 1 0 0 0

FIG. 2

Cohort-Specific Analyses of PFS, ITT Population

Cohort	Total (n)	Chemo+PL n=225 Events	Chemo+PL n=225 Median (Mo)	Chemo+BV n=459 Events	Chemo+BV n=459 Median (Mo)	HR (95% CI)
All Subjects	684	184/225	5.1	372/459	7.2	0.77 (0.64-0.93)
Chemo						
Taxanes	304	84/103	5.8	151/201	8.0	0.64 (0.49-0.84)
Gemcitabine	160	43/52	5.5	84/108	6.0	0.90 (0.61-1.32)
Capecitabine	144	39/47	4.1	87/97	6.9	0.73 (0.49-1.08)
Vinorelbine	76	18/23	7.0	50/53	5.7	1.42 (0.78-2.59)

FIG. 3



*Includes only patients with measurable disease at baseline.
**Not significant at pre-specified α=0.01; duration of response: 7.3 in chemo/BV vs. 7.5 months in chemo/PL.

FIG. 4